[HTML][HTML] Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1
P Bastard, E Orlova, L Sozaeva, R Lévy… - Journal of Experimental …, 2021 - rupress.org
Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with
APS-1 | Journal of Experimental Medicine | Rockefeller University Press Skip to Main Content …
APS-1 | Journal of Experimental Medicine | Rockefeller University Press Skip to Main Content …
Higher COVID-19 pneumonia risk associated with anti-IFN-α than with anti-IFN-ω auto-Abs in children
P Bastard, A Gervais, M Taniguchi, L Saare… - Journal of Experimental …, 2024 - rupress.org
We found that 19 (10.4%) of 183 unvaccinated children hospitalized for COVID-19
pneumonia had autoantibodies (auto-Abs) neutralizing type I IFNs (IFN-α2 in 10 patients …
pneumonia had autoantibodies (auto-Abs) neutralizing type I IFNs (IFN-α2 in 10 patients …
Autoantibodies against type I IFNs in patients with life-threatening COVID-19
P Bastard, LB Rosen, Q Zhang, E Michailidis… - Science, 2020 - science.org
INTRODUCTION Interindividual clinical variability is vast in humans infected with severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), ranging from silent infection to …
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), ranging from silent infection to …
Neutralizing type‐I interferon autoantibodies are associated with delayed viral clearance and intensive care unit admission in patients with COVID‐19
MS Abers, LB Rosen, OM Delmonte… - Immunology and cell …, 2021 - Wiley Online Library
Type‐I interferons (IFNs) mediate antiviral activity and have emerged as important immune
mediators during coronavirus disease 19 (COVID‐19). Several lines of evidence suggest …
mediators during coronavirus disease 19 (COVID‐19). Several lines of evidence suggest …
The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies
J Manry, P Bastard, A Gervais… - Proceedings of the …, 2022 - National Acad Sciences
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection fatality rate (IFR)
doubles with every 5 y of age from childhood onward. Circulating autoantibodies …
doubles with every 5 y of age from childhood onward. Circulating autoantibodies …
Mild COVID-19 despite autoantibodies against type I IFNs in autoimmune polyendocrine syndrome type 1
C Meisel, B Akbil, T Meyer, E Lankes… - The Journal of …, 2021 - Am Soc Clin Investig
Autoantibodies against IFN-α and IFN-ω (type I IFNs) were recently reported as causative for
severe COVID-19 in the general population. Autoantibodies against IFN-α and IFN-ω are …
severe COVID-19 in the general population. Autoantibodies against IFN-α and IFN-ω are …
Harnessing type I IFN immunity against SARS-CoV-2 with early administration of IFN-β
Since December 2019, over 150 million individuals have been infected with SARS-CoV-2
globally. While most cases (> 95%) are asymptomatic or mild, a small proportion develop …
globally. While most cases (> 95%) are asymptomatic or mild, a small proportion develop …
Autoantibodies neutralizing type I IFNs are present in~ 4% of uninfected individuals over 70 years old and account for~ 20% of COVID-19 deaths
P Bastard, A Gervais, T Le Voyer, J Rosain… - Science …, 2021 - science.org
Circulating autoantibodies (auto-Abs) neutralizing high concentrations (10 ng/ml; in plasma
diluted 1: 10) of IFN-α and/or IFN-ω are found in about 10% of patients with critical COVID …
diluted 1: 10) of IFN-α and/or IFN-ω are found in about 10% of patients with critical COVID …
Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs
P Bastard, SE Vazquez, J Liu, MT Laurie… - Science …, 2023 - science.org
Life-threatening “breakthrough” cases of critical COVID-19 are attributed to poor or waning
antibody (Ab) response to SARS-CoV-2 vaccines in individuals already at risk. Preexisting …
antibody (Ab) response to SARS-CoV-2 vaccines in individuals already at risk. Preexisting …
Antibodies against type I interferon: detection and association with severe clinical outcome in COVID‐19 patients
D Goncalves, M Mezidi, P Bastard… - Clinical & …, 2021 - Wiley Online Library
Objectives Impairment of type I interferon (IFN‐I) immunity has been reported in critically ill
COVID‐19 patients. This defect can be explained in a subset of patients by the presence of …
COVID‐19 patients. This defect can be explained in a subset of patients by the presence of …